PPARG and colitis: With the exception of one contradictory study showing that long-term pretreatment with a PPARγ agonist aggravated colitis [97], the preventive activation of PPARγ was efficient, whereas the efficacy of ligand administration after the onset of the disease was dependent on the levels of PPARγ [95, 98–100].